Related Experiment Video
Updated: Oct 29, 2025
Murine Dermal Fibroblast Isolation by FACS
Published on: January 7, 2016
Validation strategies for identifying drug targets in dermal fibrotic disorders
Leyla Norouzi-Barough1, Ardeshir Bayat2
1Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Abstract:
Fibrotic skin disorders, such as keloid disease (KD), are common clinically challenging disorders with unknown etiopathogenesis and ill-defined treatment strategies that affect millions of people worldwide. Thus, there is an urgent need to discover novel therapeutics. The validation of potential drug targets is an obligatory step in discovering and developing new therapeutic agents for the successful treatment of dermal fibrotic conditions, such as KD. The integration of multi-omics data with traditional and modern technological approaches, such as RNA interference (RNAi) and genome-editing tools, would provide unique opportunities to identify and validate novel targets in KD during early drug development. Thus, in this review, we summarize the current and emerging drug discovery process with a focus on validation strategies of potential drug targets identified in dermal fibrosis.
Insights
Discovering new treatments for fibrotic skin disorders like keloid disease (KD) requires validating drug targets. This review explores innovative methods for identifying and validating targets in dermal fibrosis.
Area of Science:
- Dermatology
- Pharmacology
- Molecular Biology
Background:
- Fibrotic skin disorders, including keloid disease (KD), are prevalent and challenging conditions with poorly understood causes and treatments.
- Millions worldwide are affected, highlighting the urgent need for novel therapeutic strategies.
Purpose of the Study:
- To review current and emerging drug discovery processes for dermal fibrotic conditions.
- To focus on the critical validation strategies for potential drug targets in keloid disease and other fibrotic skin disorders.
Main Methods:
- Integration of multi-omics data.
- Application of traditional and modern technological approaches, including RNA interference (RNAi) and genome-editing tools.
- Review of target identification and validation methodologies.
Main Results:
- The review synthesizes existing knowledge on drug discovery for fibrotic skin conditions.
- It emphasizes the importance of robust target validation in early drug development.
- Emerging technologies offer new avenues for identifying and validating therapeutic targets.
Conclusions:
- Effective treatment strategies for dermal fibrosis are lacking, necessitating novel therapeutic discoveries.
- Target validation is a crucial step in developing new drugs for fibrotic skin disorders.
- Advanced techniques like multi-omics and genome editing are key to identifying and validating novel targets in keloid disease.
